title: EXAMINE: targeting risk and treatment in diabetes - Authors' reply.
authors.affiliation: Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06032, USA. Electronic address: wwhite@uchc.edu.
authors.forename: William B
authors.initials: WB
authors.lastname: White
authors.affiliation: Takeda Development Center Americas, Deerfield, IL, USA.
authors.forename: Stuart
authors.initials: S
authors.lastname: Kupfer
authors.affiliation: Institut Lorrain du Coeur et des Vaisseaux, Centre d'Investigation Clinique Inserm, 54500 Vandoeuvre-Les-Nancy, France.
authors.forename: Faiez
authors.initials: F
authors.lastname: Zannad
mesh_terms: D054058:Acute Coronary Syndrome / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000517:prevention & control*; D058065:Diabetic Cardiomyopathies / Q000517:prevention & control*; D005260:Female; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D008297:Male; D010880:Piperidines / Q000009:adverse effects*; D014498:Uracil / Q000031:analogs & derivatives*
chemical_list: D007004:Hypoglycemic Agents; D010880:Piperidines; D014498:Uracil